Project

Lilly RHCF SPIRIT

Completed · 2017 until 2021

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2017
End Date
2021
Financing
Industry
Study Design
Psoriasis, Arthritis, Biologika naïve, adalimumab, ixekizumab
Brief description/objective

A 52-Week Multicenter, Randomized, Open-Label, Parallel-
Group Study Evaluating the Efficacy and Safety of
Ixekizumab versus Adalimumab in Patients with Psoriatic
Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic
Drug Naive